DK1063995T3 - Kombination til behandling af alkoholafhængighed indeholdende en opiod-antagonist og en NMDA-receptorkompleks-modulator - Google Patents

Kombination til behandling af alkoholafhængighed indeholdende en opiod-antagonist og en NMDA-receptorkompleks-modulator

Info

Publication number
DK1063995T3
DK1063995T3 DK99916907T DK99916907T DK1063995T3 DK 1063995 T3 DK1063995 T3 DK 1063995T3 DK 99916907 T DK99916907 T DK 99916907T DK 99916907 T DK99916907 T DK 99916907T DK 1063995 T3 DK1063995 T3 DK 1063995T3
Authority
DK
Denmark
Prior art keywords
nmda receptor
receptor complex
opioid antagonist
combination
complex modulator
Prior art date
Application number
DK99916907T
Other languages
English (en)
Inventor
Martine Daoust
Yves Le Buclay Bonhomme
Philippe Durbin
Original Assignee
Merck Sante Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sante Sas filed Critical Merck Sante Sas
Application granted granted Critical
Publication of DK1063995T3 publication Critical patent/DK1063995T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK99916907T 1998-03-26 1999-03-26 Kombination til behandling af alkoholafhængighed indeholdende en opiod-antagonist og en NMDA-receptorkompleks-modulator DK1063995T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98400723A EP0945133A1 (en) 1998-03-26 1998-03-26 Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator
PCT/EP1999/002337 WO1999048500A1 (en) 1998-03-26 1999-03-26 Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a nmda receptor complex modulator

Publications (1)

Publication Number Publication Date
DK1063995T3 true DK1063995T3 (da) 2003-03-10

Family

ID=8235311

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99916907T DK1063995T3 (da) 1998-03-26 1999-03-26 Kombination til behandling af alkoholafhængighed indeholdende en opiod-antagonist og en NMDA-receptorkompleks-modulator

Country Status (18)

Country Link
US (1) US6512009B1 (da)
EP (2) EP0945133A1 (da)
KR (1) KR20010034678A (da)
AT (1) ATE230993T1 (da)
AU (1) AU758569B2 (da)
BR (1) BR9909138A (da)
CA (1) CA2325739C (da)
CZ (1) CZ296367B6 (da)
DE (1) DE69904922T2 (da)
DK (1) DK1063995T3 (da)
ES (1) ES2190205T3 (da)
HK (1) HK1032542A1 (da)
HU (1) HU226555B1 (da)
NO (1) NO319313B1 (da)
PL (1) PL193241B1 (da)
RU (1) RU2226107C2 (da)
SK (1) SK284623B6 (da)
WO (1) WO1999048500A1 (da)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8052982B2 (en) 1998-07-20 2011-11-08 Peptech Animal Health Pty Limited Bioimplant formulation comprising lecithin and stearin
BR9912275A (pt) * 1998-07-20 2001-04-17 Peptech Ltd Formulação de bioimplante
WO2001052851A1 (en) * 2000-01-22 2001-07-26 Albert Shulman Methods for the treatment of substance abuse
EP1262196A3 (en) * 2001-05-23 2002-12-18 Pfizer Products Inc. Combination of a monoamine reuptake inhibitor and an opioid antagonist for use in alcoholism and alcohol dependence
DE10129265A1 (de) * 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
ES2187288B1 (es) * 2001-09-24 2004-09-16 Garbil Pharma Investigacion Chile Ltda Aminas como agentes anti-alcoholismo.
PT2561860T (pt) 2002-05-31 2018-05-08 Titan Pharmaceuticals Inc Dispositivo polimérico implantável para a libertação prolongada de buprenorfina
SI1575569T1 (sl) 2002-12-13 2010-12-31 Durect Corp Oralni sistem dostave zdravila, ki obsega visokoviskozne tekoče nosilne materiale
US20040224020A1 (en) * 2002-12-18 2004-11-11 Schoenhard Grant L. Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats
ES2359977T3 (es) 2003-03-31 2011-05-30 Titan Pharmaceuticals, Inc. Dispositivo polimérico implantable para liberación sostenida de agonista de dopamina.
WO2004110400A2 (en) * 2003-05-30 2004-12-23 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of nalmefene
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
CA2673481A1 (en) * 2006-12-19 2008-06-26 University Of Virginia Patent Foundation Combined effects of topiramate and ondansetron on alcohol consumption
CA2706931C (en) * 2007-12-06 2015-05-12 Durect Corporation Oral pharmaceutical dosage forms
US8697361B2 (en) 2008-02-28 2014-04-15 University Of Virginia Patent Foundation Serotonin transporter gene and treatment of alcoholism
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
LT2801625T (lt) 2010-07-02 2018-03-12 University Of Virginia Patent Foundation Molekulinis genetinis būdas, skirtas priklausomybės nuo alkoholio ir narkotikų gydymui ir diagnozavimui
US20130096173A1 (en) 2011-09-09 2013-04-18 Bankole A. Johnson Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence
RU2476209C1 (ru) * 2012-02-29 2013-02-27 Станислав Анатольевич Кедик Имплантируемое лекарственное средство на основе налтрексона для лечения пациентов, зависимых от алкоголя или опиатов
EP2983468A4 (en) 2013-03-15 2016-09-07 Durect Corp COMPOSITIONS WITH RHEOLOGY MODIFIER TO REDUCE RESOLUTION VARIABILITY
GB201308440D0 (en) * 2013-05-10 2013-06-19 Dalgleish Angus Therapeutic
WO2023023038A1 (en) * 2021-08-17 2023-02-23 Yale University Treatment compositions and methods

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997033581A1 (en) * 1996-03-13 1997-09-18 Yale University Smoking cessation treatments using naltrexone and related compounds

Also Published As

Publication number Publication date
HK1032542A1 (en) 2001-07-27
EP1063995B1 (en) 2003-01-15
BR9909138A (pt) 2000-12-05
EP1063995A1 (en) 2001-01-03
HUP0101546A2 (hu) 2001-09-28
RU2226107C2 (ru) 2004-03-27
HUP0101546A3 (en) 2002-10-28
KR20010034678A (ko) 2001-04-25
AU3522699A (en) 1999-10-18
DE69904922T2 (de) 2004-01-08
DE69904922D1 (de) 2003-02-20
CZ20003525A3 (cs) 2001-04-11
PL193241B1 (pl) 2007-01-31
ATE230993T1 (de) 2003-02-15
US6512009B1 (en) 2003-01-28
NO319313B1 (no) 2005-07-11
NO20004788L (no) 2000-11-24
CZ296367B6 (cs) 2006-02-15
SK284623B6 (sk) 2005-08-04
NO20004788D0 (no) 2000-09-25
CA2325739A1 (en) 1999-09-30
PL343069A1 (en) 2001-07-30
WO1999048500A1 (en) 1999-09-30
CA2325739C (en) 2007-05-15
HU226555B1 (en) 2009-03-30
EP0945133A1 (en) 1999-09-29
SK14282000A3 (sk) 2001-05-10
ES2190205T3 (es) 2003-07-16
AU758569B2 (en) 2003-03-27

Similar Documents

Publication Publication Date Title
DK1063995T3 (da) Kombination til behandling af alkoholafhængighed indeholdende en opiod-antagonist og en NMDA-receptorkompleks-modulator
DK0800519T3 (da) Steroidreceptormodulatorforbindelser og fremgangsmåder
DK0918774T3 (da) Androgenreceptormodulatorforbindelser og fremgangsmåder
NO20031266D0 (no) Kondenserte heterocykliske suksinimid-forbindelser og analoger derav, modulatorer for nukle¶r hormonreseptorfunksjon
ATE339406T1 (de) Chinazoline verbindungen als heilmittel
DK0812195T3 (da) Farmaceutisk sammensætning til piperidinoalkanolforbindelser
ID29994A (id) Komposisi farmasi untuk melawan ccr5 terdiri dari turunan anilida
DK1035833T3 (da) Sammensætning til nasal indgivelse
DK0760661T3 (da) Farmaceutiske sammensætninger omfattende en opiat-antagonist og calciumsalte, deres anvendelse til behandling af endorfin-m
DE60019334D1 (de) Antivirale arznei
DE60039878D1 (de) XENON ALS NMDA-ANTOGONIST zur Neuroprotektion
DE69836678D1 (de) Chinolin- und chinazolinderivate als antagonisten des corticotropin freisetzenden faktors (crf)
DK0810883T3 (da) Konjugat indeholdende DTPA og albumin til individuel dosering af lægemidler
MXPA01008993A (es) Tratamiento de combinacion para depresion y ansiedad.
EE200100520A (et) N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena
DE60134735D1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
MX9708394A (es) Composicion farmaceutica que contiene clorhidrato de tiagabina y el proceso para su preparacion.
DK0758312T3 (da) Substituerede fusionerede og broforbundne bicykliske forbindelser som terapeutiske midler
SE0004827D0 (sv) Therapeutic compounds
DE60114597D1 (de) Naphthamid-neurokinin antagonisten zur verwendung als medikamente
NO982562L (no) Sammensetning for behandling av smerte
DE60010934D1 (de) Medikamente geeignet zur Behandlung von proliferativen Erkrankungen
BR0311881A (pt) Combinações de inbidores de pde-v e antagonistas de nk1 para o tratamento de depressão
HUP9902723A2 (hu) Olanzapin alkalmazása migrénes fájdalom kezelésére szolgáló gyógyszerkészítmény előállítására